Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics (NASDAQ:ALGS) reported a Q1 2024 GAAP EPS of $(0.22), missing the $(0.19) estimate, with sales of $986K, down 63.79% YoY from $2.723M. Despite the miss, the loss per share improved by 58.49% from $(0.53) last year.
May 07, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aligos Therapeutics reported a Q1 2024 EPS of $(0.22), missing estimates, with a significant sales decline but improved loss per share.
Missing the EPS estimate and reporting a significant year-over-year decline in sales are negative indicators that could lead to a short-term decrease in stock price. However, the improvement in loss per share compared to the previous year might offer some mitigation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100